CSS
TEVA icon

Cubist Systematic Strategies’s Teva Pharmaceuticals TEVA Stock Holding History

Cubist Systematic Strategies’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-347,500
Closed -$5.82M – 3552
2025
Q2 		$5.82M Buy
347,500
+3,500
+1% +$56.5K 0.03% 923
2025
Q1 		$5.29M Buy
+344,000
New +$6.14M 0.03% 859
2024
Q1 		– Sell
-38,700
Closed -$404K – 4263
2023
Q4 		$404K Sell
38,700
-9,700
-20% -$90.6K ﹤0.01% 2635
2023
Q3 		$494K Hold
48,400
– – ﹤0.01% 2320
2023
Q2 		$364K Sell
48,400
-1,700
-3% -$13.8K ﹤0.01% 2549
2023
Q1 		$443K Hold
50,100
– – ﹤0.01% 2747
2022
Q4 		$457K Buy
+50,100
New +$437K ﹤0.01% 3088

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Cubist Systematic Strategies's TEVA Position: Q4 2024 in Review

Cubist Systematic Strategies sold out of Teva Pharmaceuticals (TEVA) in Q4 2024, closing a stake of 190,244 shares — an estimated $3.43M sold.

Cubist Systematic Strategies first reported a position in TEVA in Q2 2014 and held it in 41 quarters. The position peaked at $8.96M in Q2 2023. 583 funds tracked by Wall St. Rank hold TEVA as of Q4 2024.

  • Cubist Systematic Strategies reported no remaining Teva Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 190,244 Teva Pharmaceuticals shares in Q4 2024, an estimated $3.43M.
  • Cubist Systematic Strategies first reported a position in Teva Pharmaceuticals in Q2 2014 and held it in 41 quarters.
  • Cubist Systematic Strategies's Teva Pharmaceuticals position peaked at $8.96M in Q2 2023.
  • 583 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2024.

Based on Cubist Systematic Strategies's 13F filing for Q4 2024, filed 14 Feb 2025.